COMT

Catechol O-methyltransferase · P21964 · COMT on Sugi Atlas →

21,030 patent compounds predicted against COMT, 12,311 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1157996	1.00	15/20
SCHEMBL92933	0.60	10/20
SCHEMBL1158214	0.56	9/20
SCHEMBL370648	0.44	9/20
SCHEMBL370649	0.44	9/20
SCHEMBL327323	0.50	8/20
SCHEMBL112181	0.55	7/20
Diethylamine (SCHEMBL643680)	0.47	7/20
Triaziquone (SCHEMBL729528)	0.44	7/20
Triaziquone (SCHEMBL1194235)	0.44	7/20
SCHEMBL114961	1.00	6/20
Water (SCHEMBL505393)	0.97	6/20
8-Hydroxy-7-Iodo-5-Quinolinesulfonic Acid (SCHEMBL94250)	0.59	6/20
Trifluoromethanesulfonic Acid (SCHEMBL1110831)	0.46	6/20
SCHEMBL327571	0.44	6/20
SCHEMBL327289	0.42	6/20
Entacapone (SCHEMBL34504)	1.00	5/20
Entacapone (SCHEMBL34505)	1.00	5/20
SCHEMBL621648	0.52	5/20
SCHEMBL957740	0.51	5/20

Clinical trials — most relevant to COMT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
COMT Polymorphism and Entacapone Efficacy	PHASE4	COMPLETED
Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)	PHASE4	COMPLETED
A Study of L-DOPA for Depression and Slowing in Older Adults	PHASE4	COMPLETED
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists	PHASE4	COMPLETED
Clozapine for Cannabis Use in Schizophrenia	PHASE4	COMPLETED
Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach	PHASE3	COMPLETED
A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.	PHASE3	COMPLETED
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)	PHASE3	COMPLETED
Cilostazol in Parkinson's Disease	PHASE2	NOT_YET_RECRUITING
A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients	PHASE2	COMPLETED
Pilot Study of Tolcapone in Smokers	PHASE2	COMPLETED
Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal	PHASE2	COMPLETED
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease	PHASE2	COMPLETED
The Effect of Perioperative Ketamine on Acute and Chronic Pain After Major Back Surgery	PHASE2	COMPLETED
Modafinil vs Placebo for the Treatment of Methamphetamine Dependence	PHASE2	COMPLETED
Differences by Sex and Genotype in the Effects of Stress on Executive Functions	PHASE1	UNKNOWN
Effects of Modafinil on Brain Function in Patients With Schizophrenia	PHASE1	COMPLETED
Catecholamine-O-Methyl-Transferase(COMT)-Polymorphism in Cardiac Surgery	nan	COMPLETED
Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls	nan	SUSPENDED
A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors	nan	COMPLETED
Compensation Mechanisms in Parkinson's Disease	nan	COMPLETED
Neurobiological Mechanisms in Panic Disorder	nan	COMPLETED
Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients	nan	COMPLETED
The Meaning of Dopaminergic Pathway in Sleep Breathing Disorders.	nan	ENROLLING_BY_INVITATION
Noninvasive Neuromodulation of the Prefrontal Cortex in Subjects With Obesity	nan	COMPLETED
Estrogen Receptor 1 Gene Polymorphism Frequency in Fibromyalgia Syndrome	nan	COMPLETED
Hodgkin's Disease and Chemotherapy Before 40 Years	nan	NOT_YET_RECRUITING
Real-Time Levodopa Level Monitoring in Parkinson Disease	nan	RECRUITING
Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia	nan	UNKNOWN
Predicting Outcomes From tDCS Intervention in Parkinson' Disease Using Electroencephalographic Biomarkers and Machine Learning Approach: the PREDICT Study Protocol	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a COMT binder may also engage these)

Protein	Name	Similarity
Q5H879	—	1.000	Q5H879 →
P22734	—	0.998	P22734 →
O88587	—	0.996	O88587 →
A7MBI7	—	0.991	A7MBI7 →
Q99028	—	0.975	Q99028 →
D3ZLY0	—	0.967	D3ZLY0 →
Q8BZG5	—	0.967	Q8BZG5 →
Q501J2	—	0.966	Q501J2 →
Q0V8R7	—	0.965	Q0V8R7 →
Q8BNV1	—	0.963	Q8BNV1 →
A5PK19	—	0.963	A5PK19 →
LPCAT1	Lysophosphatidylcholine acyltransferase 1	0.963	landscape →
Q8HZJ0	—	0.962	Q8HZJ0 →
Q14CH1	—	0.962	Q14CH1 →
Q1HAQ0	—	0.961	Q1HAQ0 →
Q3TFD2	—	0.961	Q3TFD2 →
Q9D1Z3	—	0.961	Q9D1Z3 →
Q5E9V4	—	0.961	Q5E9V4 →
Q9DD20	—	0.961	Q9DD20 →
Q9QXT4	—	0.961	Q9QXT4 →
Q8BIG7	—	0.960	Q8BIG7 →
O95671	—	0.960	O95671 →
Q96CB9	—	0.960	Q96CB9 →
Q86VU5	—	0.960	Q86VU5 →
Q6AYG0	—	0.960	Q6AYG0 →
F1NZI4	—	0.959	F1NZI4 →
P46597	—	0.959	P46597 →
F4ZGF2	—	0.959	F4ZGF2 →
Q9D0Z3	—	0.959	Q9D0Z3 →
Q9CXT6	—	0.958	Q9CXT6 →